Final analysis of a phase 3 trial in 751 participants with 1p/19q non-co-deleted anaplastic glioma: adjuvant temozolomide with radiotherapy improved overall survival (HR 0.65), concurrent did not (HR 0.91). Exploratory IDH-mutant median OS: 12.5 vs 6.0 years.
RCTn = 751
van den Bent et al. Concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): final and exploratory analyses of a randomised, open-label, phase 3 trial